Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VINO-AC Plus VINO-CPO vs VAC Plus VINO-CPO in High Risk Rhabdomyosarcoma
NCT04994132Phase 3Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Sep 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of vinorelbine in rhabdomyosarcoma (RMS) (2 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-free survival at 5 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
vinorelbine
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT04994132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994132.